These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12032882)

  • 1. Technologies for measuring HIV-1 drug resistance.
    Schmidt B; Korn K; Walter H
    HIV Clin Trials; 2002; 3(3):227-36. PubMed ID: 12032882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic drug resistance interpretation systems--the cutting edge of antiretroviral therapy.
    Schmidt B; Walter H; Zeitler N; Korn K
    AIDS Rev; 2002; 4(3):148-56. PubMed ID: 12416449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding HIV-1 drug resistance.
    Frenkel LM; Tobin NH
    Ther Drug Monit; 2004 Apr; 26(2):116-21. PubMed ID: 15228150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
    Hirsch MS; Conway B; D'Aquila RT; Johnson VA; Brun-Vézinet F; Clotet B; Demeter LM; Hammer SM; Jacobsen DM; Kuritzkes DR; Loveday C; Mellors JW; Vella S; Richman DD
    JAMA; 1998 Jun; 279(24):1984-91. PubMed ID: 9643863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-GRADE: a publicly available, rules-based drug resistance interpretation algorithm integrating bioinformatic knowledge.
    Obermeier M; Pironti A; Berg T; Braun P; Däumer M; Eberle J; Ehret R; Kaiser R; Kleinkauf N; Korn K; Kücherer C; Müller H; Noah C; Stürmer M; Thielen A; Wolf E; Walter H
    Intervirology; 2012; 55(2):102-7. PubMed ID: 22286877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and uses of a public HIV drug-resistance database.
    Shafer RW
    J Infect Dis; 2006 Sep; 194 Suppl 1(Suppl 1):S51-8. PubMed ID: 16921473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.
    Torre D; Tambini R
    HIV Clin Trials; 2002; 3(1):1-8. PubMed ID: 11819179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
    Aceti A; Carosi G
    Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
    Hanna GJ; D'Aquila RT
    Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of resistance testing in the management of HIV-1-infected patients.
    Grant PM; Zolopa AR
    Curr Opin HIV AIDS; 2009 Nov; 4(6):474-80. PubMed ID: 20048713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 genotypic and phenotypic resistance.
    Hanna GJ
    Clin Lab Med; 2002 Sep; 22(3):637-49. PubMed ID: 12244590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral resistance testing for clinical management.
    Youree BE; D'Aquila RT
    AIDS Rev; 2002; 4(1):3-12. PubMed ID: 11998782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The legal proceeding on the use of genotypic assays for the detection of HIV antiretroviral resistance in Italy: background and rationale for a consensus conference to establish guidelines.
    Ippolito G; Visco-Comandini U; Nicastri E
    Scand J Infect Dis Suppl; 2003; 106():8-11. PubMed ID: 15000574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of drug resistance assays in testing HIV-1 non-B subtypes.
    Holguín A; Hertogs K; Soriano V
    Clin Microbiol Infect; 2003 Apr; 9(4):323-6. PubMed ID: 12667245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computer-Aided Optimization of Combined Anti-Retroviral Therapy for HIV: New Drugs, New Drug Targets and Drug Resistance.
    Zazzi M; Cozzi-Lepri A; Prosperi MC
    Curr HIV Res; 2016; 14(2):101-9. PubMed ID: 26511342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral drug resistance testing.
    Sen S; Tripathy SP; Paranjape RS
    J Postgrad Med; 2006; 52(3):187-93. PubMed ID: 16855319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system.
    Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F
    J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.